An experimental drug slows the progression of early-stage Alzheimer’s

An experimental drug slows the progression of early-stage Alzheimer’s

A clinical trial with the drug donanemab managed to “significantly” slow down the clinical progression of early-stage symptomatic Alzheimer’s disease.

The results of the phase 3 trial were already released by the pharmaceutical company Lilly last May and are now published in the Jama magazine.

The trial involved 1,736 participants between the ages of 60 and 85 and the drug donanemab, a monoclonal antibody designed to kill brain amyloid plaque.

One of the early manifestations of Alzheimer’s is the abnormal accumulation of beta-amyloid peptide.which can form large plaques in the brain and disrupt synapse function, as well as the formation of tau protein tangles.

The experimental drug “significantly slowed clinical progression at 76 weeks” among participants with early symptomatic Alzheimer’s disease and amyloid and tau pathology.

Along with the study, Jama publishes an analysis signed by Gil Rabinovici, director of the Alzheimer’s Disease Research Center at the University of California at San Francisco (UCSF), who was not involved in the research.

Rabinovici recalled that with this new drug (still awaiting authorization for its use) sThere are already three treatments available (donanemab, aducanumab and lecanemab) and that this field “begins to show progress in the fight to stop” Alzheimer’s.

The expert pointed out that these drugs work best in the earliest stages of the disease and other therapies will be needed to help advanced patients.

The trial showed that donanemab slowed cognitive decline by 35% compared to placebo in patients with low to intermediate brain tau levels.

Patients also experienced a 40% lower risk of transitioning from mild cognitive impairment to mild dementia, or from mild to moderate dementia.

Rabinovici noted that the experimental drug cleared amyloid plaques better than the other two and reduced tau levels in the blood, “but not in a key area of ​​the brain.” The scientist considered these results “encouraging” but further analysis is still needed to understand how these findings affect patient outcomes.

Also, those with more advanced disease showed little or no benefit compared with those who received the placebo. Rabinovici recalled that the drug can have potentially serious side effects, which should push experts to “aim higher in developing more impactful and safe treatments.”

Like the other two drugs already available, donanemab was associated with amyloid-related imaging abnormalities (ARIA), a side effect that can involve swelling in areas of the brain and microbleeding.

In this case, this side effect occurred in 24% of the cases and in 3.7% it was serious, with three deaths that were considered related to the treatment.

The risks were higher among patients with the APOE4 gene, which is linked to an increased risk of Alzheimer’s, so Rabinovici believes genetic testing should be recommended before monoclonal antibody treatment.

Donanemab should be limited to patients with low to intermediate tau levels, indicating mild disease, while other trials are evaluating the efficacy of monoclonal antibodies in the early phase of the disease, before symptoms appear.

The expert highlights as one of the main limitations of the trial that only 8.6% of the American participants were not white.which raises ethical issues regarding the “generalization of the results to populations at higher risk”.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!